JPH07508281A - 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物 - Google Patents

光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物

Info

Publication number
JPH07508281A
JPH07508281A JP6502537A JP50253793A JPH07508281A JP H07508281 A JPH07508281 A JP H07508281A JP 6502537 A JP6502537 A JP 6502537A JP 50253793 A JP50253793 A JP 50253793A JP H07508281 A JPH07508281 A JP H07508281A
Authority
JP
Japan
Prior art keywords
sibutramine
pharmaceutically acceptable
composition
stereoisomer
humans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6502537A
Other languages
English (en)
Japanese (ja)
Inventor
ヤング，ジェイムズ　ダブリュ．
Original Assignee
セプラコア　インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セプラコア　インコーポレーテッド filed Critical セプラコア　インコーポレーテッド
Publication of JPH07508281A publication Critical patent/JPH07508281A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP6502537A 1992-06-23 1993-06-22 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物 Pending JPH07508281A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90303492A 1992-06-23 1992-06-23
US903,034 1992-06-23
PCT/US1993/005967 WO1994000047A1 (en) 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine

Publications (1)

Publication Number Publication Date
JPH07508281A true JPH07508281A (ja) 1995-09-14

Family

ID=25416828

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6502537A Pending JPH07508281A (ja) 1992-06-23 1993-06-22 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物

Country Status (5)

Country Link
EP (1) EP0708639A4 (de)
JP (1) JPH07508281A (de)
AU (1) AU4542993A (de)
CA (1) CA2139000A1 (de)
WO (1) WO1994000047A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504303A (ja) * 1998-12-02 2003-02-04 ピーター・スターリング・ミュラー 器質性障害から派生する障害の治療
JP2012051904A (ja) * 1999-03-19 2012-03-15 Abbott Gmbh & Co Kg 変形性関節症の治療

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
DK1360169T3 (da) 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
GB2098601B (en) * 1981-04-02 1985-07-24 Sandoz Products Ltd Improvements in or relating to organic compounds
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504303A (ja) * 1998-12-02 2003-02-04 ピーター・スターリング・ミュラー 器質性障害から派生する障害の治療
JP2012051904A (ja) * 1999-03-19 2012-03-15 Abbott Gmbh & Co Kg 変形性関節症の治療

Also Published As

Publication number Publication date
EP0708639A4 (de) 1997-08-20
AU4542993A (en) 1994-01-24
EP0708639A1 (de) 1996-05-01
CA2139000A1 (en) 1994-01-06
WO1994000047A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
JP4664505B2 (ja) ビュープロピオン代謝物質ならびにその合成方法および使用
JPH07508281A (ja) 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
SWEET et al. Mental symptoms in Parkinson's disease during chronic treatment with levodopa
JPH08500093A (ja) 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
EP1904066B1 (de) KOMBINATIONEN VON ESZOPICLON UND TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALINAMIN ZUR BEHANDLUNG DER MENOPAUSE, Perimenopause UND VON KOGNITIVEN STÖRUNGEN
KR101185322B1 (ko) 약제 제조용 밀나시프란의 (1에스,2알) 거울상이성체의용도
JP2003501344A (ja) （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
WO2006053186A2 (en) Method for treatment of movement disorders
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
CZ20013607A3 (cs) Farmaceutický prostředek
JP2009500420A (ja) エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
Parkes et al. Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings
KR102623984B1 (ko) 칸나비노이드 조성물, 및 파킨슨병 및 알츠하이머병을 비롯한 신경 퇴행성 질환을 치료하기 위한 약물의 제조에서 이의 용도
JPH0227327B2 (de)
US20020006963A1 (en) Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
CA2654557A1 (en) Combination preparations comprising bifeprunox and l-dopa
EP4021433B1 (de) Behandlung von menstruationszyklusinduzierten symptomen
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
CA2654719A1 (en) Combination preparations comprising slv308 and a l-dopa
CN117500490A (zh) 用于治疗执行功能障碍的组合治疗
AU2022396274A1 (en) Therapy selection and treatment of neurodegenerative disorders
WO2019103597A1 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
JP2007511577A (ja) （２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノールの使用